Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

Shares of Moderna tumbled Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year.

The main reason for this week's decline is that Moderna lowered its 2025 full-year revenue guidance, and by a wide margin.

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.

Moderna stock has been under pressure amid declining sales of its COVID-19 vaccine. The company projects ... Notably, the company maintains a robust balance sheet to support these objectives ...

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock ...

Don't share food or drinks with a person infected with the disease, and make sure to wash any potentially contaminated sheets ... no vaccine against norovirus. But researchers at Moderna are ...

Shares of Lululemon Athletica Inc. ( N/A ) were higher by 0.9 per cent on Monday after it raised its current-quarter targets, ...

It feels fantastic,” said Blau, who thanked her lab members and colleagues for their support and dedication. “This ...

Key Takeaways Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck ...

B iotechnology stocks are among the most high-risk, high-reward stocks in the market. Many biotech companies are working to develop one or or even a handful of world-changing drug ...